What are the recommended starting dose, administration instructions, monitoring parameters, and dose adjustment guidelines for deferasirox in patients with chronic transfusional iron overload such as thalassemia, sickle‑cell disease, or myelodysplastic syndromes?

Deferasirox Dosing and Management in Transfusional Iron Overload

Start deferasirox at 14 mg/kg orally once daily in patients ≥2 years old with eGFR >60 mL/min/1.73 m² who have received ≥100 mL/kg of packed red blood cells (approximately ≥20 units for a 40 kg person) and serum ferritin consistently >1000 mcg/L 1.

Patient Selection Criteria

Before initiating therapy, confirm the patient meets these requirements:

• Transfusion burden: ≥100 mL/kg of packed RBCs (≥20 units for adults ≥40 kg) 1
• Serum ferritin: Consistently >1000 mcg/L 1
• Renal function: eGFR >60 mL/min/1.73 m² (do not use if eGFR <40) 1

For MDS patients specifically, NCCN guidelines recommend considering chelation when patients have received or are anticipated to receive >20 RBC transfusions with serum ferritin >2500 ng/mL, targeting reduction to <1000 ng/mL 2.

Administration Instructions

• Timing: Once daily, preferably at the same time each day 1
• Food: On an empty stomach OR with a light meal (<7% fat, ~250 calories) 1
• Method: Swallow whole tablets with water or other liquids 1
• Crushing: May crush and mix with soft foods (yogurt, applesauce) if swallowing difficulty; consume immediately 1
• Avoid: Do not take with aluminum-containing antacids 1

Baseline Monitoring Requirements

Before starting therapy, obtain 1:

• Serum ferritin level
• Renal function (critical for safety):
  • Serum creatinine in duplicate (due to measurement variability)
  • Calculate eGFR using CKD-EPI or MDRD for adults; Schwartz equation for pediatrics
  • Urinalysis and serum electrolytes to evaluate tubular function
• Liver function: Serum transaminases and bilirubin
• Auditory and ophthalmic examinations

Dose Adjustments During Therapy

Monitoring Schedule

• Monthly: Serum ferritin, blood counts, liver function, renal function 1
• Dose adjustments: Every 3-6 months based on ferritin trends 1

Titration Based on Ferritin

Dose increases (in 3.5 or 7 mg/kg increments) 1:

• If ferritin persistently >2500 mcg/L without decreasing trend, may increase up to 28 mg/kg
• Never exceed 28 mg/kg/day 1

Dose reductions:

• If ferritin falls below 1000 mcg/L at 2 consecutive visits, consider reducing dose (especially if >17.5 mg/kg/day) 1

Interrupt therapy:

• If ferritin falls below 500 mcg/L, stop deferasirox and continue monthly monitoring 1

Renal Function Adjustments (Critical Safety Issue)

Adults: If serum creatinine increases ≥33% above baseline 1:

• Repeat within 1 week
• If still elevated ≥33%, reduce dose by 7 mg/kg

Pediatrics: If eGFR decreases >33% below baseline 1:

• Reduce dose by 7 mg/kg
• Repeat eGFR within 1 week
• Interrupt therapy during acute illnesses causing volume depletion (vomiting, diarrhea, decreased oral intake)
• Resume only when oral intake and volume status normalize

Special Populations

Baseline Hepatic Impairment 1

• Mild (Child-Pugh A): No adjustment needed
• Moderate (Child-Pugh B): Reduce starting dose by 50%
• Severe (Child-Pugh C): Avoid deferasirox

Baseline Renal Impairment 1

• eGFR 40-60 mL/min/1.73 m²: Reduce starting dose by 50%; use minimum effective dose with frequent monitoring
• eGFR <40 mL/min/1.73 m²: Contraindicated 1

Critical Safety Warnings

Black Box Warning 2: Postmarketing reports include:

• Acute renal failure (some fatal)
• Hepatic failure (some fatal)
• Cytopenias (agranulocytosis, neutropenia, thrombocytopenia)
• Gastrointestinal bleeding

Most fatalities occurred in patients with multiple comorbidities and advanced hematologic disease stages.

Common Pitfalls to Avoid

1. Age-related toxicity: Deferasirox appears poorly tolerated in SCD patients >40 years with established organ complications; heightened vigilance for renal and hepatic toxicity is essential 3

2. Volume depletion in pediatrics: Always interrupt therapy during acute illnesses causing dehydration 1

3. Inadequate dosing: Real-world data suggest doses ≥30 mg/kg/day may be needed for iron balance in some patients, though FDA maximum is 28 mg/kg 4, 5

4. Initial ferritin rise: Expect a paradoxical ferritin increase in the first 4 weeks before continuous decline begins 6

Evidence Quality Note

The FDA label 1 provides the most authoritative dosing guidance (14 mg/kg starting dose for the tablet formulation). NCCN guidelines 2 offer disease-specific thresholds for MDS. Large prospective studies 4 support tailoring doses to transfusional iron intake with ferritin-guided titration, though these used the older dispersible tablet formulation requiring ~30% higher dosing than current tablets.